Damora Therapeutics (DMRA)

Healthcare · Biotechnology
$21.08 +2.53% on the day Market cap $1.3B 52-week range $4.95 to $38.33 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Damora Therapeutics's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from DMRA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation1
Profitability0
Financial health9

Results from SEC filings

Fiscal years, from Damora Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue—————
Net income-$52M-$62M-$38M-$21M-$210M
Free cash flow-$53M-$43M———
EPS (diluted)-$51.25-$60.75-$36.08-$18.53$3.98
Operating margin—————

Superinvestors who own DMRA

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Andreas Halvorsen
Viking Global Investors
Held $60M0.17%Q2 2026

Insider buying

Open-market purchases by Damora Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Sep 25, 2026 Jennifer Jarrett
Director, President and CEO
12,500$20.23$252,875

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when DMRA trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Damora Therapeutics insiders buying the stock?

1 open-market insider purchase of DMRA in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Damora Therapeutics?

1 of the superinvestors Investingly tracks hold DMRA in their latest 13F, including Andreas Halvorsen.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.